DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Huperzine A is an investigational drug.
There have been 12 clinical trials for Huperzine A. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Intracranial Hemorrhage, Hypertensive. The leading clinical trial sponsors are Biscayne Neurotherapeutics, Inc., Melbourne Health, and National Institute on Aging (NIA).
Recent Clinical Trials for Huperzine A
|Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage||Jiangsu Famous Medical Technology Co., Ltd.||Phase 4|
|BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures||Biscayne Neurotherapeutics Australia Pty, Ltd.||Phase 1/Phase 2|
|BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures||Biscayne Neurotherapeutics, Inc.||Phase 1/Phase 2|